227 related articles for article (PubMed ID: 34877513)
1. Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis.
Vosoughi K; Atieh J; Khanna L; Khoshbin K; Prokop LJ; Davitkov P; Murad MH; Camilleri M
EClinicalMedicine; 2021 Dec; 42():101213. PubMed ID: 34877513
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review.
Xie Z; Yang S; Deng W; Li J; Chen J
Clin Epidemiol; 2022; 14():1463-1476. PubMed ID: 36510488
[TBL] [Abstract][Full Text] [Related]
3. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ
Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Li Z; Zhang Y; Quan X; Yang Z; Zeng X; Ji L; Sun F; Zhan S
PLoS One; 2016; 11(5):e0154206. PubMed ID: 27158818
[TBL] [Abstract][Full Text] [Related]
6. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
Li WX; Gou JF; Tian JH; Yan X; Yang L
Curr Ther Res Clin Exp; 2010 Aug; 71(4):211-38. PubMed ID: 24688145
[TBL] [Abstract][Full Text] [Related]
8. Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis.
Zhuo C; Lin C; Zhou C; Gao X; Shao H; Fang T; Tian H; Ding L; Liu M
Front Pharmacol; 2021; 12():759262. PubMed ID: 35002700
[No Abstract] [Full Text] [Related]
9. [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
Li ZX; Wu SS; Yang ZR; Zhan SY; Sun F
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):454-9. PubMed ID: 27318907
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.
Jiang Y; Liu J; Chen X; Yang W; Jia W; Wu J
Adv Ther; 2021 Mar; 38(3):1470-1482. PubMed ID: 33582976
[TBL] [Abstract][Full Text] [Related]
11. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
[TBL] [Abstract][Full Text] [Related]
13. Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.
Chubb B; Gupta P; Gupta J; Nuhoho S; Kallenbach K; Orme M
Diabetes Ther; 2021 May; 12(5):1325-1339. PubMed ID: 33723769
[TBL] [Abstract][Full Text] [Related]
14. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.
Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Ji L; Zhan S
Endocrine; 2015 Apr; 48(3):794-803. PubMed ID: 25115635
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis.
Xia L; Shen T; Dong W; Su F; Wang J; Wang Q; Niu S; Fang Y
Diabetes Res Clin Pract; 2021 Jul; 177():108904. PubMed ID: 34102249
[TBL] [Abstract][Full Text] [Related]
16. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
Monami M; Dicembrini I; Marchionni N; Rotella CM; Mannucci E
Exp Diabetes Res; 2012; 2012():672658. PubMed ID: 22675341
[TBL] [Abstract][Full Text] [Related]
17. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
[TBL] [Abstract][Full Text] [Related]
18. Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis.
Alsugair HA; Alshugair IF; Alharbi TJ; Bin Rsheed AM; Tourkmani AM; Al-Madani W
Healthcare (Basel); 2021 Aug; 9(9):. PubMed ID: 34574899
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
Nauck MA; Quast DR
Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
